Clinical Trials Logo

Clinical Trial Summary

The proGait-study is a two-arm exercise intervention study for AYA-patients with lower extremity tumor endoprosthesis in the follow-up care. This clinical trial will investigate the effects of an 8-week personalized multi-modal exercise intervention of lower extremity muscles on gait quality in adolescents and young adults with cancer diagnosis beginning at least 12 months after endoprosthesis implantation.


Clinical Trial Description

The main objective of the proGait-study is to investigate the effects of an 8-week personalized, partially supervised exercise program for lower extremity muscles on gait kinematics of adolescents and young adults, who are in follow-up care after cancer treatment and at least 12 months after endoprosthesis implantation. This randomized controlled trial will include n=20-30 patients. Patients will be randomly assigned to the intervention or control group. Patients in the intervention group will perform two supervised exercise sessions in week one and two. In the following weeks, they will perform in a mix of supervised and unsupervised exercise sessions to introduce the patients into independent exercise. Both groups receive recommendations for individual lower extremity exercise. Secondary aims of this interventional study are to evaluate functional mobility, knee range of motion and patient-reported outcomes including QoL and fatigue. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04963517
Study type Interventional
Source Universität Duisburg-Essen
Contact
Status Completed
Phase Phase 2/Phase 3
Start date August 7, 2021
Completion date May 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05621668 - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Phase 1
Not yet recruiting NCT05515068 - Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Active, not recruiting NCT00592293 - Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas N/A
Recruiting NCT05051059 - Assessment of the Functional Outcome and Quality of Life in Sarcoma Patients N/A
Recruiting NCT06129903 - Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma N/A
Completed NCT06202599 - Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
Recruiting NCT04634227 - Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot) Early Phase 1
Recruiting NCT03277924 - Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas Phase 1/Phase 2
Active, not recruiting NCT03462316 - NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma Phase 1
Recruiting NCT04055220 - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas N/A
Completed NCT02520128 - A Study of IMRT in Primary Bone and Soft Tissue Sarcoma N/A
Completed NCT02301039 - SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Phase 2
Recruiting NCT06409013 - Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma
Withdrawn NCT05116800 - Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Phase 2
Recruiting NCT04181970 - Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Completed NCT00525057 - Dalteparin in Preventing DVT in Participants With Cancer N/A
Recruiting NCT04698785 - Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients Phase 2
Completed NCT01588522 - Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease Phase 1
Terminated NCT03468075 - Gemcitabine Plus Ascorbate for Sarcoma in Adults Phase 2